June 12 (Reuters) - Lexaria Bioscience Corp LEXX.O:
LEXARIA BIOSCIENCE CORP - ENTERS CHANGE ORDER TO TERMS OF ITS PROJECT AGREEMENT WITH NOVOTECH - SEC FILING
LEXARIA BIOSCIENCE CORP - CHANGE ORDER ADDS 5TH STUDY ARM FOR DEHYDRATECH-TIRZEPATIDE CAPSULES IN ITS AUSTRALIAN CLINICAL STUDY- SEC FILING
LEXARIA BIOSCIENCE CORP - CHANGE ORDER RESULTS IN ADDITIONAL COSTS OF AU$1.9 MILLION - SEC FILING
Source text: [ID:n0001640334-25-001030]
Further company coverage: LEXX.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.